EcoDrugPlus

Phospholipase A2 Group X

Ensembl ID : ENSOTSG00005030565
Gene Symbol: PLA2G10
1 Cross references
225 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSOTSG00005045697
Gene Symbol: GART
1 Cross references
239 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSOTSG00005011584
Gene Symbol: PLAT
3 Cross references
199 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSOTSG00005019575
Gene Symbol: PLAT
3 Cross references
199 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSOTSG00005043254
Gene Symbol: LOC112217598
3 Cross references
250 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSOTSG00005025189
Gene Symbol: LOC112250159
3 Cross references
250 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOTSG00005036889
Gene Symbol: PTAFR
1 Cross references
214 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOTSG00005022155
Gene Symbol: PTAFR
1 Cross references
209 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOTSG00005036890
Gene Symbol: PTAFR
1 Cross references
214 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOTSG00005036887
Gene Symbol: PTAFR
1 Cross references
208 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSOTSG00005016000
Gene Symbol: PDGFRB
3 Cross references
174 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSOTSG00005008472
Gene Symbol: LOC112217868
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).